Neurocrine, Idorsia part ways 2 years after collab's double phase 2 fails

Two years after Idorsia and Neurocrine’s calcium channel blocker flunked a pair of phase 2 studies in quick succession, the biotechs have finally decided to part ways.

Idorsia had initially taken the candidate, dubbed NBI-827104, into the clinic on the strength of evidence that the molecule could enter the brain and block channels associated with epilepsies. Neurocrine took an interest in 2019, paying a $5 million fee to form a collaboration before handing over a further $45 million the following year to take up its option on the program.